EUVIMEDOpdag EUVIMED
Crossref

Machine Learning‐Based Discovery of a Novel Noncovalent MurA Inhibitor as an Antibacterial Agent

Qingxin Liu iD, Aoqi Luo, Hongwei Jin, Xinxin Si, Ming Li

Chemical Biology & Drug Design · 2025-03 · 105 (3)

DOI: 10.1111/cbdd.70084 ↗

At a glance

Journal article in Chemical Biology & Drug Design, published online on 2025-03-12. Written by Qingxin Liu and 4 co-authors. Institution: School of Pharmacy, Jiangsu Ocean University, Lianyungang, Jiangsu, China. Major MEDLINE topics: Anti-Bacterial Agents, Enzyme Inhibitors, Machine Learning, Molecular Docking Simulation. Cited 3 times so far (Crossref); 51 references. Funded by: Priority Academic Program Development of Jiangsu Higher Education Institutions.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

The bacterial cell wall is crucial for maintaining the integrity of bacterial cells. UDP‐N‐acetylglucosamine 1‐carboxyethylene transferase (MurA) is an important enzyme involved in bacterial cell wall synthesis. Therefore, it is an important target for antibacterial drug research. Although many MurA inhibitors have been discovered, only fosfomycin is still used as a MurA inhibitor in clinical practice. Owing to the long‐term use of fosfomycin, the emergence of fosfomycin resistance is worrisome. Therefore, it is still necessary to discover new MurA inhibitors with different types of action than fosfomycin. In this study, we used AutoMolDesigner to construct a machine learning model combined with molecular docking to screen for noncovalent MurA inhibitors. We subsequently conducted the MurA inhibition activity assay and identified compound L16 (N‐(3‐(benzo[d]oxazol‐2‐yl)‐4‐hydroxyphenyl) carbamoyl‐4‐methylbenzamide) as a moderately active MurA inhibitor (IC 50 = 26.63 ± 1.60 μM). The compound was structurally different from other known MurA inhibitors. We used molecular dynamics simulation to reveal possible interactions between the compound and MurA. In addition, we also found that compound L16 was nontoxic to human liver cancer cells (HepG2) (IC 50 > 100 μM). In conclusion, through virtual screening and in vitro biological evaluation, we identified a novel structural type of MurA inhibitor which may become a candidate drug for inhibiting bacterial cell wall synthesis.

Subjects

MeSH terms (MEDLINE)

Anti-Bacterial AgentsEnzyme InhibitorsMachine LearningMolecular Docking SimulationAlkyl and Aryl TransferasesHumansDrug DiscoveryMicrobial Sensitivity TestsMolecular Dynamics SimulationTransferases

Author keywords

AutoMolDesignerMurAantibacterial agentmachine learningvirtual screening

Substances

Anti-Bacterial AgentsEnzyme InhibitorsTransferasesUDP-N-acetylglucosamine 1-carboxyvinyltransferaseAlkyl and Aryl Transferases

Authors and institutions

  • School of Pharmacy, Jiangsu Ocean University, Lianyungang, Jiangsu, China.
  • State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, China.
  • Department of Pharmacy, Lianyungang Affiliated Hospital of Nanjing University of Chinese Medicine, Lianyungang, China.

ORCID profiles: Qingxin Liu

Funding

  • Priority Academic Program Development of Jiangsu Higher Education Institutions

Cite

APA

Liu, Q., Luo, A., Jin, H., Si, X., & Li, M. (2025). Machine Learning‐Based Discovery of a Novel Noncovalent MurA Inhibitor as an Antibacterial Agent. Chemical Biology & Drug Design, 105(3). https://doi.org/10.1111/cbdd.70084

Vancouver

Liu Q, Luo A, Jin H, Si X, Li M. Machine Learning‐Based Discovery of a Novel Noncovalent MurA Inhibitor as an Antibacterial Agent. Chemical Biology & Drug Design. 2025;105(3). doi:10.1111/cbdd.70084

BibTeX
@article{Liu2025,
  author = {Liu, Qingxin and Luo, Aoqi and Jin, Hongwei and Si, Xinxin and Li, Ming},
  title = {Machine Learning‐Based Discovery of a Novel Noncovalent MurA Inhibitor as an Antibacterial Agent},
  journal = {Chemical Biology & Drug Design},
  year = {2025},
  volume = {105},
  number = {3},
  doi = {10.1111/cbdd.70084}
}
Start for free →